Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Landos Biopharma stock
Learn how to easily invest in Landos Biopharma stock.
Landos Biopharma Inc is a biotechnology business based in the US. Landos Biopharma shares (LABP) are listed on the NASDAQ and all prices are listed in US Dollars. Landos Biopharma employs 33 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Landos Biopharma
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – LABP – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Landos Biopharma stock price (NASDAQ: LABP)Use our graph to track the performance of LABP stocks over time.
Landos Biopharma shares at a glance
|Latest market close||$3.25|
|52-week range||$2.78 - $16.99|
|50-day moving average||$6.26|
|200-day moving average||$11.03|
|Wall St. target price||$26.08|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.97|
Buy Landos Biopharma shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Landos Biopharma stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Landos Biopharma price performance over time
|1 week (2022-01-20)||4.50%|
|1 month (2021-12-28)||-34.08%|
|3 months (2021-10-28)||-75.75%|
|6 months (2021-07-28)||-71.89%|
|1 year (2021-01-24)||N/A|
|2 years (2020-01-24)||N/A|
|3 years (2019-01-24)||N/A|
|5 years (2017-01-24)||N/A|
Landos Biopharma financials
|Revenue TTM||$18 million|
|Gross profit TTM||$0|
|Return on assets TTM||-26.28%|
|Return on equity TTM||-48.35%|
|Market capitalisation||$150.9 million|
TTM: trailing 12 months
Landos Biopharma share dividends
We're not expecting Landos Biopharma to pay a dividend over the next 12 months.
Landos Biopharma overview
Landos Biopharma, Inc. , a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases. The company also develops NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1, a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and PX-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and rheumatoid arthritis. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia. .
Landos Biopharma in the news
Ackman takes a big stake in Netflix, excited about company's long-term prospects
What to watch today: Stock futures turn positive, reversing big overnight losses
5 things to know before the stock market opens Thursday
Frequently asked questionsWhat percentage of Landos Biopharma is owned by insiders or institutions?
Currently 32.93% of Landos Biopharma shares are held by insiders and 56.47% by institutions. How many people work for Landos Biopharma?
Latest data suggests 33 work at Landos Biopharma. When does the fiscal year end for Landos Biopharma?
Landos Biopharma's fiscal year ends in December. Where is Landos Biopharma based?
Landos Biopharma's address is: 1800 Kraft Drive, Blacksburg, VA, United States, 24060-6370 What is Landos Biopharma's ISIN number?
Landos Biopharma's international securities identification number is: US5150691021
More guides on Finder
Walmart dives deep into the metaverse with crypto and NFTs
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump has an NFT — what to know before you buy
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Vigorus (VIS) price prediction
Read our expert analysis on Vigorus and how the token will perform in the future.
Dogecoin jumps 10% on word you can use it to buy Tesla merch
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
Thursday’s top U.S. stocks: Taiwan Semiconductor Manufacturing Company Ltd. (TSM ↑8.4%), Lam Research Corporation (LRCX ↑6.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Ask an Expert